Billionaire Israel Englander’s 10 Stock Picks with Huge Upside Potential

5. IQVIA Holdings Inc. (NYSE:IQV)

Number of Hedge Fund Holders as of Q4: 51

Millennium Management’s Equity Stake: $269.33 Million 

Upside Potential as of April 26: 41.57%

Ranking fifth among billionaire Israel Englander’s stock picks with huge upside potential, IQVIA Holdings Inc. (NYSE:IQV) is a leading global provider of clinical research services, commercial insights, and healthcare intelligence. The company was recently recognized as a “front-runner generative AI leader” for the life sciences industry by Everest Group. IQVIA was the only CRO to receive the highest ranking of front-runner, reflecting the value impact of its end-to-end generative AI capabilities. Additionally, IQVIA stands out as the only CRO with a dedicated technology business unit to achieve this distinction.

In its fourth-quarter financial results, IQVIA Holdings Inc. (NYSE:IQV) reported earnings per share (EPS) of $3.12, slightly above the analyst estimate of $3.11. Revenue for the quarter came in at $3.96 billion, surpassing the consensus estimate of $3.93 billion. Looking ahead, IQVIA projects full-year 2025 EPS between $11.70 and $12.10, compared to the analyst consensus of $11.88. The company also expects full-year 2025 revenue to range between $15.73 billion and $16.13 billion, closely aligned with the consensus estimate of $16.03 billion.

In the fourth quarter of 2024, Millennium Management increased its stake in the company by 302%. By the end of the December quarter, it held over 1.37 million shares in IQVIA Holdings Inc. (NYSE:IQV), valued at over $269 million, as compared to 341,237 by the end of the previous quarter. The growing hedge fund investment underscores the fund’s strong confidence in IQVIA’s growth potential.

Hardman Johnston Global Equity Strategy stated the following regarding IQVIA Holdings Inc. (NYSE:IQV) in its Q4 2024 investor letter:

“The top sector detractors from relative performance during the quarter were Health Care and Consumer Discretionary. Within Health Care, the top detracting holdings were IQVIA Holdings Inc. (NYSE:IQV) and Elanco Animal Health, Inc. IQVIA is a contract research organization (CRO) serving biopharma industry. The company lowered its 2024 guidance due to disruptions on the clinical side of the business, with one large cancellation and two trial starts pushed into 2025. Short-term disruptions in this segment should get resolved during the first half of 2025. However, the Technology and Analytical Solutions side of the business had a positive quarter, returning to growth, with outlook for continued growth in 2025.”